Battery-operated skin patch offers new option for migraine sufferers

March 26, 2013
Battery-operated skin patch offers new option for migraine sufferers
FDA recently approved Zecuity patch to treat the painful headaches.

(HealthDay)—The first skin patch approved to treat migraines offers patients an alternative to pills, nasal sprays and injections, the U.S. Food and Drug Administration says.

The agency approved the Zecuity patch in January 2013 as a treatment for migraines after they begin. The patch contains sumatriptan (brand name Imitrex), a widely prescribed drug for treating migraines, and wraps around the arm or thigh like an ACE bandage.

"Although consumers are familiar with using a patch for, say, , this is the first patch the FDA has approved to treat migraines," Dr. Eric Bastings, a neurologist and deputy director of the FDA's Division of Neurology, said in an agency news release.

The battery-powered Zecuity patch uses an electrical current to move the drug through the skin over the course of four hours. A computer chip regulates the charge to ensure the patients receive the proper dosage.

There are some drawbacks, however.

The patch, which is about 8 inches long and 4 inches wide, is large enough that it can show when worn under short-sleeved shirts or shorts, and requires some privacy to put it on.

"For many people, popping a pill is a lot more immediate and simple," Bastings said.

But he noted that other methods of taking migraine medications also have downsides. The can leave an unpleasant aftertaste and some people are uncomfortable with giving themselves injections.

"Many experience debilitating pain—sometimes so acute that they can't swallow a pill," Bastings added.

In a clinical study, about 25 percent of patients complained of a painful sensation at the patch application site, while others were unhappy with the skin reddening that most patients developed after using the patch.

More than 30 million Americans suffer from migraines, according to the FDA.

More information: The U.S. National Institute of Neurological Disorders and Stroke has more about migraines.

Related Stories

FDA approves first skin patch to combat migraines

January 21, 2013

(HealthDay News) —A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.

Recommended for you

Viruses thrive in big families, in sickness and in health

August 5, 2015

The BIG LoVE (Utah Better Identification of Germs-Longitudinal Viral Epidemiology) study, led by scientists at the University of Utah School of Medicine, finds that each bundle of joy puts the entire household at increased ...

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.